Literature DB >> 29951301

Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.

Rebecca Tay1, Arsela Prelaj1,2, Raffaele Califano1,3,4.   

Abstract

Immune checkpoint blockade has shown anti-tumour activity and improved survival in advanced non-small cell lung cancer (NSCLC). A number of anti-PD-1/PD-L1 and CTLA-4 monoclonal antibody agents have been evaluated in metastatic non-small cell lung cancer. Nivolumab, pembrolizumab and atezolizumab are currently approved for use in clinical practice due to demonstrated improvement in response rate, overall survival (OS) and quality of life (QoL) over standard chemotherapy. We present a series of cases that highlight the clinical challenges that these novel agents present. A review of rare immune-related adverse events (AEs), optimal treatment duration and patient selection will be presented. This series will also address real-life clinical scenarios such as treatment re-challenge and management of immune-related AEs.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); adverse events (AEs); atezolizumab; durvalumab; immune checkpoint blockade; nivolumab; pembrolizumab

Year:  2018        PMID： 29951301      PMCID： PMC5994491          DOI： 10.21037/jtd.2018.01.80

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  36 in total

1.  Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Authors:  Jeffrey Weber; Geoffrey Gibney; Ragini Kudchadkar; Bin Yu; Pingyan Cheng; Alberto J Martinez; Jodie Kroeger; Allison Richards; Lori McCormick; Valerie Moberg; Heather Cronin; Xiuhua Zhao; Michael Schell; Yian Ann Chen
Journal:  Cancer Immunol Res       Date:  2016-02-12       Impact factor: 11.151

2.  Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

Authors:  H Helgadottir; L Kis; P Ljungman; J Larkin; R Kefford; P A Ascierto; J Hansson; G Masucci
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

4.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

5.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

6.  Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Authors:  Jeffrey S Weber; Reinhard Dummer; Veerle de Pril; Celeste Lebbé; F Stephen Hodi
Journal:  Cancer       Date:  2013-02-07       Impact factor: 6.860

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

9.  Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Authors:  James Larkin; David Minor; Sandra D'Angelo; Bart Neyns; Michael Smylie; Wilson H Miller; Ralf Gutzmer; Gerald Linette; Bartosz Chmielowski; Christopher D Lao; Paul Lorigan; Kenneth Grossmann; Jessica C Hassel; Mario Sznol; Adil Daud; Jeffrey Sosman; Nikhil Khushalani; Dirk Schadendorf; Christoph Hoeller; Dana Walker; George Kong; Christine Horak; Jeffrey Weber
Journal:  J Clin Oncol       Date:  2017-07-03       Impact factor: 44.544

10.  PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.

Authors:  Francesco Passiglia; Giuseppe Bronte; Viviana Bazan; Clara Natoli; Sergio Rizzo; Antonio Galvano; Angela Listì; Giuseppe Cicero; Christian Rolfo; Daniele Santini; Antonio Russo
Journal:  Oncotarget       Date:  2016-04-12
View more
  3 in total

1.  NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score.

Authors:  Peng Song; Dongliang Yang; Xiaoxia Cui; Hanping Wang; Xiaoyan Si; Xiaotong Zhang; Li Zhang
Journal:  Cancer Manag Res       Date:  2020-07-17       Impact factor: 3.989

2.  Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Authors:  Xiaoying Sun; Raheleh Roudi; Ting Dai; Shangya Chen; Bin Fan; Hongjin Li; Yaqiong Zhou; Min Zhou; Bo Zhu; Chengqian Yin; Bin Li; Xin Li
Journal:  BMC Cancer       Date:  2019-06-10       Impact factor: 4.430

3.  An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors.

Authors:  Babak Baseri; Bachar Samra; Eric Tam; Edwin Chiu; Andrea Leaf
Journal:  Case Rep Oncol Med       Date:  2019-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.